The assessment discusses fifty eight peptides in different clinical phases, indicating a strong pipeline of peptide therapies targeting PPIs. These kinds of synthesizers are particularly beneficial for laboratory-scale peptide synthesis, generating the specified peptides swiftly for additional structural and practical studies. On the other hand,